Senti Bio to Present at the Citizens JMP Life Sciences Conference
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotech company focused on next-generation cell and gene therapies, has announced its upcoming presentation at the Citizens JMP Life Sciences Conference in New York. The presentation is scheduled for May 8th, 2025, at 1:00 PM ET.
Dr. Timothy Lu, Co-Founder and CEO, will lead the presentation, which will highlight recent positive preliminary clinical results of their lead program, SENTI-202, in treating patients with Relapsed/Refractory AML. Management will also be available for one-on-one meetings with qualified investors attending the conference.
Interested parties can access the live video webcast through Senti Bio's website investor section and will remain available for 90 days after the event.
Senti Biosciences (Nasdaq: SNTI), un'azienda biotecnologica in fase clinica specializzata in terapie cellulari e geniche di nuova generazione, ha annunciato la sua prossima presentazione alla Citizens JMP Life Sciences Conference a New York. La presentazione è prevista per l'8 maggio 2025 alle 13:00 ET.
Il dott. Timothy Lu, co-fondatore e CEO, guiderà la presentazione, durante la quale verranno illustrati i recenti risultati clinici preliminari positivi del loro programma principale, SENTI-202, nel trattamento di pazienti con leucemia mieloide acuta recidivante/refrattaria. Il management sarà inoltre disponibile per incontri individuali con investitori qualificati presenti alla conferenza.
Gli interessati potranno seguire la diretta video in streaming attraverso la sezione investitori del sito web di Senti Bio; la registrazione resterà disponibile per 90 giorni dopo l'evento.
Senti Biosciences (Nasdaq: SNTI), una empresa biotecnológica en etapa clínica enfocada en terapias celulares y génicas de próxima generación, ha anunciado su próxima presentación en la Citizens JMP Life Sciences Conference en Nueva York. La presentación está programada para el 8 de mayo de 2025 a la 1:00 PM ET.
El Dr. Timothy Lu, cofundador y CEO, liderará la presentación, que destacará los recientes resultados preliminares positivos de su programa principal, SENTI-202, en el tratamiento de pacientes con leucemia mieloide aguda en recaída/refractaria. La dirección también estará disponible para reuniones individuales con inversores calificados que asistan a la conferencia.
Los interesados podrán acceder a la transmisión en vivo a través de la sección de inversores en el sitio web de Senti Bio, y estará disponible durante 90 días después del evento.
Senti Biosciences (나스닥: SNTI)는 차세대 세포 및 유전자 치료에 중점을 둔 임상 단계 바이오텍 회사로, 뉴욕에서 열리는 Citizens JMP 생명과학 컨퍼런스에서 곧 발표를 진행할 예정입니다. 발표는 2025년 5월 8일 오후 1시(동부시간)에 예정되어 있습니다.
공동 창립자 겸 CEO인 Dr. Timothy Lu가 발표를 이끌며, 재발성/불응성 급성 골수성 백혈병(AML) 환자를 치료하는 주요 프로그램 SENTI-202의 최근 긍정적인 초기 임상 결과를 강조할 예정입니다. 경영진은 또한 컨퍼런스에 참석하는 적격 투자자들과 일대일 미팅도 진행할 예정입니다.
관심 있는 분들은 Senti Bio 웹사이트의 투자자 섹션을 통해 생중계 영상을 시청할 수 있으며, 이벤트 종료 후 90일간 다시보기 서비스를 이용할 수 있습니다.
Senti Biosciences (Nasdaq : SNTI), une société biotechnologique en phase clinique spécialisée dans les thérapies cellulaires et géniques de nouvelle génération, a annoncé sa prochaine présentation lors de la Citizens JMP Life Sciences Conference à New York. La présentation est prévue pour le 8 mai 2025 à 13h00 ET.
Le Dr Timothy Lu, cofondateur et PDG, dirigera la présentation qui mettra en lumière les résultats cliniques préliminaires positifs récents de leur programme principal, SENTI-202, dans le traitement des patients atteints de leucémie myéloïde aiguë en rechute/réfractaire. La direction sera également disponible pour des réunions individuelles avec des investisseurs qualifiés présents à la conférence.
Les personnes intéressées pourront accéder à la diffusion vidéo en direct via la section investisseurs du site web de Senti Bio, disponible pendant 90 jours après l'événement.
Senti Biosciences (Nasdaq: SNTI), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Zell- und Gentherapien der nächsten Generation, hat seine bevorstehende Präsentation auf der Citizens JMP Life Sciences Conference in New York angekündigt. Die Präsentation ist für den 8. Mai 2025 um 13:00 Uhr ET geplant.
Dr. Timothy Lu, Mitgründer und CEO, wird die Präsentation leiten, in der die jüngsten positiven vorläufigen klinischen Ergebnisse ihres führenden Programms SENTI-202 zur Behandlung von Patienten mit rezidivierender/refraktärer AML vorgestellt werden. Das Management steht zudem für Einzelgespräche mit qualifizierten Investoren auf der Konferenz zur Verfügung.
Interessierte können die Live-Videoübertragung über den Investor-Bereich der Senti Bio-Website verfolgen; die Aufzeichnung ist 90 Tage nach der Veranstaltung verfügbar.
- Positive preliminary clinical results reported for SENTI-202 in Relapsed/Refractory AML treatment
- CEO presenting at major life sciences investor conference, increasing visibility
- None.
Live video webcast presentation on Thursday, May 8th at 1:00 PM ET
Presentation will highlight the recently announced positive preliminary clinical results of lead program, SENTI-202, in the treatment of patients with Relapsed/Refractory AML
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences will present on Thursday, May 8, 2025 at 1:00 PM ET at the Citizens JMP Life Sciences Conference being held in New York, NY.
In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.sentibio.com) and will be accessible for 90 days following the live event.
About Senti Bio
Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
FAQ
When will Senti Bio (SNTI) present at the Citizens JMP Life Sciences Conference 2025?
How can investors watch Senti Bio's JMP Conference presentation live?
What will Senti Bio's presentation at JMP Conference cover about SENTI-202?
Can investors meet with Senti Bio management at the JMP Life Sciences Conference?
What is Senti Bio's main technology platform mentioned in the conference announcement?
